213 related articles for article (PubMed ID: 19032736)
1. Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells.
Fujiwara M; Izuishi K; Sano T; Hossain MA; Kimura S; Masaki T; Suzuki Y
J Exp Clin Cancer Res; 2008 Nov; 27(1):76. PubMed ID: 19032736
[TBL] [Abstract][Full Text] [Related]
2. Phosphoinositide-3-kinase inhibition enhances radiosensitization of cervical cancer in vivo.
Liu Y; Cui B; Qiao Y; Zhang Y; Tian Y; Jiang J; Ma D; Kong B
Int J Gynecol Cancer; 2011 Jan; 21(1):100-5. PubMed ID: 21330835
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo.
Bondar VM; Sweeney-Gotsch B; Andreeff M; Mills GB; McConkey DJ
Mol Cancer Ther; 2002 Oct; 1(12):989-97. PubMed ID: 12481421
[TBL] [Abstract][Full Text] [Related]
4. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
5. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
6. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002.
Gupta AK; Cerniglia GJ; Mick R; Ahmed MS; Bakanauskas VJ; Muschel RJ; McKenna WG
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):846-53. PubMed ID: 12788194
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
Badinloo M; Esmaeili-Mahani S
Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.
Xie X; Tang B; Zhou J; Gao Q; Zhang P
Oncol Rep; 2013 Aug; 30(2):773-82. PubMed ID: 23743572
[TBL] [Abstract][Full Text] [Related]
9. Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas.
Van Meter TE; Broaddus WC; Cash D; Fillmore H
Cancer; 2006 Nov; 107(10):2446-54. PubMed ID: 17041888
[TBL] [Abstract][Full Text] [Related]
10. LY294002 potentiates the anti-cancer effect of oxaliplatin for gastric cancer via death receptor pathway.
Liu J; Fu XQ; Zhou W; Yu HG; Yu JP; Luo HS
World J Gastroenterol; 2011 Jan; 17(2):181-90. PubMed ID: 21245990
[TBL] [Abstract][Full Text] [Related]
11. PI3K/Akt inhibitor partly decreases TNF-α-induced activation of fibroblast-like synoviocytes in osteoarthritis.
Liu S; Cao C; Zhang Y; Liu G; Ren W; Ye Y; Sun T
J Orthop Surg Res; 2019 Dec; 14(1):425. PubMed ID: 31829201
[TBL] [Abstract][Full Text] [Related]
12. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the phosphatidylinositol 3'-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac.
Yip-Schneider MT; Wiesenauer CA; Schmidt CM
J Gastrointest Surg; 2003; 7(3):354-63. PubMed ID: 12654560
[TBL] [Abstract][Full Text] [Related]
14. TCF21 inhibits proliferation and chemoresistance through the AKT pathway in human gastric cancer.
Yang Z; Jiang X; Li D; Dong Q; Zhao H; Jiang X
Gene; 2019 Jan; 682():42-49. PubMed ID: 30296564
[TBL] [Abstract][Full Text] [Related]
15. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
Mao Y; Xi L; Li Q; Cai Z; Lai Y; Zhang X; Yu C
Oncol Rep; 2016 Jul; 36(1):49-56. PubMed ID: 27220401
[TBL] [Abstract][Full Text] [Related]
16. Smad3 Sensitizes Hepatocelluar Carcinoma Cells to Cisplatin by Repressing Phosphorylation of AKT.
Zhou HH; Chen L; Liang HF; Li GZ; Zhang BX; Chen XP
Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27110775
[TBL] [Abstract][Full Text] [Related]
17. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.
Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772
[TBL] [Abstract][Full Text] [Related]
18. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
[TBL] [Abstract][Full Text] [Related]
19. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways augment the sensitivity to actinomycin D in Ewing sarcoma.
Yamamoto T; Ohno T; Wakahara K; Nagano A; Kawai G; Saitou M; Takigami I; Matsuhashi A; Yamada K; Shimizu K
J Cancer Res Clin Oncol; 2009 Aug; 135(8):1125-36. PubMed ID: 19205734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]